Wedbush Rates Damora Therapeutics (DMRA) buy, $35 Price Target

Wedbush has reiterated its buy rating on Damora Therapeutics with a price target of $35, a 69.99% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:11 PM EDT · Updated Jun 18, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wedbush rated Damora Therapeutics, Inc. ($DMRA) "buy" with a $35 price target on June 12, 2026.

Since the rating, $DMRA is up 15.0% after 1 week, up 34.7% after 1 month and down 11.3% to date (from the $20.78 close on Jun 12, 2026).

DMRA Damora Therapeutics, Inc.

$18.44 -15.49% year to date

Daily close · Oct 16, 2026

Key Points

Wedbush reiterated a buy rating on Damora Therapeutics, Inc. (DMRA) with a target price of $35 on June 12, 2026.
Wedbush's $35 price target implies 69.99% upside from Damora Therapeutics, Inc.'s ($DMRA) current $20.59 share price.
The stock is currently trading at $20.59, down from its previous close of $22.59.
Analysts have a consensus strong buy rating, with an average price target of $44.67 based on nine opinions.

Get $DMRA trade alerts by text

We text you when insiders, Congress or big funds trade $DMRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Damora Therapeutics, Inc. alert may contain errors. Disclosures

Wedbush's Continued Confidence in Damora Therapeutics

Wedbush has reiterated its buy rating on Damora Therapeutics, Inc. (DMRA) with a price target of $35. This announcement was made on June 12, 2026. The stock is currently trading at $20.59, down from its previous close of $22.59, reflecting a notable shift in the market's sentiment.

Analysts Set New Price Targets

This is not the first time Wedbush has shown support for Damora Therapeutics. The firm has maintained a positive outlook on the company, as seen in their previous ratings. On September 29, 2026, they reiterated an outperform rating with a target of $40. Other analysts have also expressed bullish sentiments, with Guggenheim maintaining a buy rating and raising their target to $60 on September 25, 2026. Jefferies initiated coverage with a buy rating and a $50 target on July 27, 2026, further solidifying the positive consensus around Damora.

Stock Performance and Market Context

Currently, Damora Therapeutics' stock is trading well below its 52-week high of $38.33, indicating potential for recovery as analysts remain optimistic. The shares have also seen significant volatility, with a 52-week low of $3.50. The stock's performance is closely watched as it approaches its next earnings date on November 5, 2026, which could provide more insights into the company's financial health.

12-month forecast

$DMRA price target

Damora Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.

What Damora Therapeutics, Inc. Does

Damora Therapeutics, Inc. is a biopharmaceutical company that focuses on developing therapies for hematologic disorders in Denmark and North America. Its lead product, DMR-001, is an investigational monoclonal antibody therapy aimed at treating essential thrombocythemia. The company aims to address various mutations in CALR and is working on additional therapies for acute myeloid leukemia.

What to Watch at Damora Therapeutics, Inc.

As Damora Therapeutics prepares for its earnings report in November, analysts will be looking closely at the company's performance and any updates on its product pipeline. This reiteration of the buy rating from Wedbush serves as a reminder of the market's expectations for the company's future growth despite recent stock fluctuations.